Evidence map›Paper›PMID 36935913›Full record

ArticlePeerJ2023

Characterization of viral pathogens associated with symptomatic upper respiratory tract infection in adults during a low COVID-19 transmission period.

Nurlan Sandybayev, Vyacheslav Beloussov, Vitaliy Strochkov, Maxim Solomadin, Joanna Granica, Sergey Yegorov

Open access · goldFull text read
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Genomic Characterization and Virulence Determinants ofAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Nurlan SandybayevKazakhstan-Japan Innovation Center, Kazakh National Agrarian Research University, Almaty, Kazakhstan.ORCID 0000-0003-1814-2798
Vyacheslav BeloussovKazakhstan-Japan Innovation Center, Kazakh National Agrarian Research University, Almaty, Kazakhstan.
Vitaliy StrochkovKazakhstan-Japan Innovation Center, Kazakh National Agrarian Research University, Almaty, Kazakhstan.ORCID 0000-0003-3399-2942
Maxim SolomadinSchool of Pharmacy, Karaganda Medical University, Karaganda, Kazakhstan.ORCID 0000-0003-4219-1055
Joanna GranicaTreeGene Molecular Genetics Laboratory, Almaty, Kazakhstan.
Sergey YegorovMichael G. DeGroote Institute for Infectious Disease Research; McMaster Immunology Research Centre; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada.ORCID 0000-0002-7136-7921
Kazakh National Agrarian Research University · KZKaraganda Medical University · KZMcMaster University Medical Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The epidemiology of respiratory tract infections (RTI) has dramatically changed over the course of the COVID-19 pandemic. A major effort in the clinical management of RTI has been directed toward diagnosing COVID-19, while the causes of other, common community RTI often remain enigmatic. To shed light on the etiological causes of RTI during a low COVID-19 transmission period in 2021, we did a pilot study using molecular testing for virologic causes of upper RTI among adults with respiratory symptoms from Almaty, Kazakhstan. Methods: Adults presenting at two public hospitals with respiratory symptoms were screened using SARS-CoV-2 PCR on nasopharyngeal swabs. A subset of RTI+, COVID-19-negative adults ( Results: Of 1,812 symptomatic adults, 21 (1.2%) tested SARS-CoV-2-positive. Within the COVID-19 negative outpatient subset, 33/50 subjects (66%) had a positive PCR result for a common community RTI virus, consisting of human parainfluenza virus 3-4 (hPIV 3-4) in 25/50 (50%), rhinovirus (hRV) in 2 (4%), hPIV4-hRV co-infection in four (8%) and adenovirus or the OCR43/HKU-1 coronavirus in two (4%) cases; no IAV was detected. Virome sequencing allowed to reconstruct sequences of most PCR-identified rhinoviruses and hPIV-3/human respirovirus-3. Conclusions: COVID-19 was cause to a low proportion of symptomatic RTI among adults. Among COVID-negative participants, symptomatic RTI was predominantly associated with hPIV and hRV. Therefore, respiratory viruses other than SARS-CoV-2 should be considered in the clinical management and prevention of adult RTI in the post-pandemic era.

Indexed as

COVID-19Influenza A virusRespiratory Tract InfectionsAdultHumansMultiplex Polymerase Chain ReactionPandemicsParainfluenza Virus 1, HumanParainfluenza Virus 2, HumanPilot ProjectsRhinovirusSARS-CoV-2Central AsiaCOVID-19Human parainfluenzaInfluenzaNGSPCRRespiratory tract infectionsRhinovirusSARS-CoV-2

Identifiers

PMID36935913
PMCPMC10022499
OpenAlexW4324066775

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read19
reference markers read2
identifiers read7
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.